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Abstract
Background: Endothelin-1 (ET-1) both stimulates nociceptors and sensitizes them to noxious
stimuli, an effect probably mediated by the ETA receptor (ETAR) expressed in sensory neurons. The
cellular mechanisms of this ET-1-mediated effect are only poorly understood. TRPV1, the heat-,
pH- and capsaicin-sensitive cation channel already known to be modulated by a number of cellular
mediators released in response to noxious stimuli and during inflammation, is a potential target for
the action of ET-1.
Results: We studied the effects of ET-1 on TRPV1 in sensory neurons from the dorsal root
ganglion (DRG) and in HEK293 cells coexpressing TRPV1 and the ETAR. Specific 125I-ET-1 binding
sites (817 ± 92 fmol/mg) were detected in membrane preparations of DRG with an ETAR/ETBR
ratio of 60:40. In an immunofluorescence analysis, coexpression of TRPV1 and the ETAR was found
in a subpopulation of primary sensory neurons. ET-1 strongly potentiated capsaicin-induced TRPV1
currents in some neurons, and in HEK293 cells co-expressing TRPV1 and the ETAR. Weaker
potentiation was observed in HEK293 cells coexpressing TRPV1 and the ETBR. ETAR activation also
increased responses to low pH and heat. In HEK293 cells, strong potentiation of TRPV1 like that
induced by ET-1 via the ETAR could be induced by PKC activation, but not with activators of the
adenylyl cyclase or the PKA pathway. Furthermore, inhibition of PKC with bisindolylmaleimide X
(BIM X) or mutation of the PKC phosphorylation site S800 completely prevented ETAR-mediated
potentiation.
Conclusion: We conclude that ET-1 potentiates TRPV1 by a PKC-dependent mechanism and that
this could play a major role in the algogenic and hyperalgesic effects of ET-1 described in previous
studies.
Published: 14 November 2007
Molecular Pain 2007, 3:35 doi:10.1186/1744-8069-3-35
Received: 10 May 2007
Accepted: 14 November 2007
This article is available from: http://www.molecularpain.com/content/3/1/35
© 2007 Plant et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Pain 2007, 3:35 http://www.molecularpain.com/content/3/1/35
Page 2 of 13
(page number not for citation purposes)
Background
Endothelin is one of many local mediators that are impor-
tant in pain generation and the modulation of nociceptor
responsiveness to painful stimuli. The endothelins, ET-1,
ET-2 and ET-3, are vasoactive peptides, originally cloned
from endothelial cells [1], but also produced by other cell
types, including some tumor cells [2-5]. Endothelins act
on ETA and ETB receptors (ETARs and ETBRs) [6,7], both G
protein-coupled receptors that can activate multiple G
protein types and influence various signaling pathways
[8].
ET-1 injection excites nociceptors [9,10] and induces
nocifensive behaviour in animals [11-13], and severe pain
and tactile allodynia in humans [14]. ET receptor antago-
nists have been reported to reduce neuropathic and
inflammatory pain, and pain in patients with metastatic
prostate cancer (see [15,16] for reviews). Given the
number of reports on the involvement of ET-1 in nocice-
ption, relatively little is known about the signaling cas-
cade and effectors that lead to the nociceptive responses to
ET-1 in primary sensory neurons.
Activation of the ETAR, which is expressed in sensory neu-
rons [17], results in small increases in [Ca2+]i in a sensory
neuron-derived cell line [18] and DRG neurons [19], and
in a protein kinase C(PKC)-ε-mediated potentiation of
Ca2+ responses to capsaicin [19]. The increased respon-
siveness of sensory neurons may result from an ETAR-
mediated lowering of the threshold for activation of tetro-
dotoxin (TTX)-insensitive Na+  channels [20], but may
involve other effectors. One possibility is that ET-1 affects
other channels like the nonselective cation channel
TRPV1, an integrator of a number of noxious stimuli,
including heat (> 42°C), capsaicin, endocannabinoids
and H+ [21], which is essential for thermal hyperalgesia in
inflammation [22,23]. TRPV1 activation results in depo-
larization and excitation of sensory neurons. In a prelim-
inary conference report we showed that activation of the
ETAR potentiated TRPV1 responses to capsaicin in HEK
293 cells [24]. A number of modulators sensitize nocicep-
tors by potentiating TRPV1 responses [25-30]. Possible
mechanisms involved in potentiation are phosphoryla-
tion via PKC-ε [31] and protein kinase A (PKA) [32,33],
disinhibition of TRPV1 by hydrolysis of phosphatidyli-
nositol bisphosphate (PIP2) [28], or modulation via
phophatidylinositol-3-kinase and extracellular signal-
related kinases 1/2 [34].
In this study, we investigated ET receptor expression in
DRG and, using the patch clamp technique, the effects of
ET-1 on responses to capsaicin in DRG neurons. A sub-
population of neurons responded to ET-1 with a potenti-
ation of the capsaicin-mediated responses. To investigate
the signaling pathways involved in potentiation, we stud-
ied the effects of ET-1 in HEK293 cells coexpressing the
ETAR and TRPV1.
Results
Endothelin receptors in dorsal root ganglion neurons
The expression of endothelin receptor subtypes in the rat
lumbar DRG was analyzed in binding experiments using
125I-ET-1 as the radioligand. Saturation binding analysis
of membranes derived from isolated lumbar DRG (L4 –
L5) revealed a maximal binding capacity of 817 ± 92
fmol/mg (mean ± SD of three measurements performed
in duplicate). When the ETAR-selective antagonist BQ123
or the ETBR-selective agonist IRL1620 were used as com-
peting ligands (to determine the amount of ETAR or ETBR
expression), binding capacities of 503 ± 115 and 313 ±
113 fmol/mg protein were obtained, respectively. Thus,
both ETARs and ETBRs are expressed in the rat DRG with
an expression ratio of 60:40.
In an immunofluorescence analysis, we further studied
the distribution of ETARs and ETBRs in tissue sections of
lumbar DRG. To probe whether ETARs and ETBRs are
expressed in small sensory neurons that express TRPV1,
we performed double staining experiments using affinity-
purified antibodies against ETARs or ETBRs in conjunction
with antibodies against TRPV1. The data show that ETARs
are widely expressed in small and medium-to-large diam-
eter neurons, and, in particular, in TRPV1-expressing
small sensory neurons (Fig. 1A). Controls with pre-
immune serum showed a weak uniform staining of all
neurons (not shown). Coexpression of the ETAR with
TRPV1 was found in 31 of 66 TRPV1-positive DRGs
(47%). ETBR expression in DRGs was, if present, relatively
weak (Fig. 1B), and not easy to distinguish from unspe-
cific staining (not shown). The staining with the ETBR
antibody showed a different pattern from that of the ETAR
and TRPV1 antibodies and surrounded the perikarya, pos-
sibly reflecting expression in satellite cells. More promi-
nent staining with the ETBR antibody was observed when
analyzing the axonal extensions of DRG, where the cells
stained by the ETB antibody were costained by antibodies
directed against the S100 antigen (Fig. 1C), indicating that
they are glia. In contrast, for the ETAR no expression was
found in glial cells (data not shown). Thus, ETAR are
found in sensory neurons, including TRPV1-positive
small diameter neurons, whereas ETBRs are mainly found
in glial cells. Our data on ETR expression in sensory neu-
rons are consistent with previous reports [17,35], which
also demonstrated ETAR expression in neurons, frequently
in small neurons together with calcitonin gene-related
peptide [17], a marker of a subpopulation of C fibers.
These studies also demonstrated ETBR expression in DRG
satellite cells and nonmyelinating Schwann cells, but not
in DRGs.Molecular Pain 2007, 3:35 http://www.molecularpain.com/content/3/1/35
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Effects of ET-1 in isolated sensory neurons
A low concentration of capsaicin (10 nM) evoked currents
through TRPV1 in a subpopulation of DRG neurons. In
the Ca2+-free extracellular solutions used to minimise the
Ca2+-dependent component of desensitization, repetitive
applications of capsaicin activated currents which were
either stable or which declined slowly. In 9/30 capsaicin-
sensitive neurons (30%), application of ET-1 (100 nM)
for 30 or 60 s prior to the application of 10 nM capsaicin
resulted in a large increase in the capsaicin-induced cur-
rent (Fig. 2A). On average, currents were increased 14.7 ±
4.1-fold (mean ± SEM, n = 8) when the first capsaicin-elic-
ited response after ET-1 treatment was compared to that
before ET-1 addition. The potentiation of the capsaicin
responses by a single application of ET-1 was transient;
the amplitude of the capsaicin-activated current declined
to different degrees in response to repetitive stimulation
in the six neurons in which three or more capsaicin
responses could be elicited after ET-1 application. How-
ever, as shown in Figure 2A, potentiation often persisted
for several minutes. In 5/9 neurons that responded to ET-
1 with a potentiation of capsaicin-induced TRPV1 activa-
tion, ET-1 alone also transiently activated an inward cur-
rent with a wide range of amplitudes (between -2.0 and -
69.3 pA/pF, mean: -25.5 ± 12.3 pA/pF, n = 5) at -60 mV
(Fig. 2B). Activation and decay of the ET-1-activated cur-
rent was rapid. The cells that responded to ET-1 with a
potentiation of capsaicin-activated currents could not be
distinguished from the non-responsive cells on the basis
of their size. Their capacitances, indicative of the cell sur-
face area, were 35.3 ± 5.9 pF (n = 8) and 39.1 ± 3.7 pF (n
= 21), respectively. In 13 of the 21 cells that did not
respond to ET-1, we subsequently tested for the ability of
bradykinin (1 µM) to potentiate capsaicin (10 nM)-acti-
vated TRPV1 currents. In 6/13 cells, bradykinin applica-
tion resulted in a potentiation of capsaicin-activated
currents through TRPV1 (16.5 ± 7.6-fold, n = 6), which
closely resembled that induced by ET-1 (data not shown).
It was notable that responses of DRGs to ET-1 were mainly
observed on the day of preparation, or on the day after
preparation. Neurons cultured for longer rarely
responded to ET-1, but did respond to bradykinin, sug-
gesting that in cultured DRGs the expression of ET recep-
tor subtypes might be down regulated or that there is an
impairment in the efficiency of coupling to downstream
signaling cascades. Loss of receptors during culture may
also explain the lower percentage of cultured capsaicin-
sensitive neurons that respond to ET-1, compared to the
percentage of DRGs coexpressing TRPV1 and ETAR in sec-
tions of ganglia.
Effects of ET-1 on HEK293 cells transiently transfected 
with TRPV1 and the ETA or ETB receptor
Owing to the small fraction of neurons that responded to
ET-1, the regulation of TRPV1 by ET-1 was analysed in
HEK293 cells transiently co-transfected with plasmids
encoding TRPV1-YFP and the ETAR or ETBR. HEK293 cells
co-expressing the ETAR and TRPV1 responded to 10 nM
capsaicin with currents that displayed the characteristic
outwardly-rectifying IV-relation of TRPV1 (Fig. 3A, B). ET-
1 application (100 nM) for 30 s or 1 minute resulted in a
large potentiation of capsaicin-activated currents through
TRPV1 (Fig. 3A – C), like that in sensory neurons. Cur-
rents recorded during the first response to capsaicin
directly after ET-1 application were increased 8.3 ± 1.5-
fold (n = 10), those in response to the second capsaicin
application, 2.5 minutes after ET-1 treatment, 10.7 ± 2.0-
fold (n = 9). In addition, in most cells, ET-1 application
resulted in the slow activation of a current, particularly in
the outward direction, with the characteristics of TRPV1
(Fig. 3A, B). However, none of the cells displayed a rapid,
transient current like that seen in DRGs, an indication that
the ET-1-activated current inn DRGs may be mediated by
a different channel.
In ETAR-expressing cells, application of ET-1 also potenti-
ated currents activated by low pH or by heat (Fig. 3D – J).
H+-activated TRPV1 currents were evoked by application
of a solution of pH 5.1, a pH which produces a submaxi-
mal TRPV1 activation, preceded by the application of a
Expression of ETARs and ETBRs in rat dorsal root ganglion Figure 1
Expression of ETARs and ETBRs in rat dorsal root 
ganglion. Sections of lumbar rat dorsal root ganglion were 
analysed for the expression of ETARs (A) or ETBRs (B, C) 
using affinity-purified antibodies. For the identification of 
TRPV1-postive neurons co-staining with a TRPV1 antibody 
(A, B) was performed. Expression of ETBRs in glial cells was 
demonstrated by co-staining of the S100 antigen (C). Bars: 20 
µm.Molecular Pain 2007, 3:35 http://www.molecularpain.com/content/3/1/35
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solution of pH 6.8 to desensitize endogenous acid-sens-
ing ion channels (ASICs; Fig. 3D) [36]. Application of ET-
1 resulted in a 9.9 ± 1.3-fold (n = 12) potentiation of the
first response to pH 5.1 after ET-1 application (Fig. 3D –
F), and a significant potentiation of subsequent responses
(Fig. 3D, F). Current responses of TRPV1 to heat were
recorded upon raising the temperature from room tem-
perature to 44°C (Fig. 3G). In controls, consecutive
responses had similar amplitudes (Fig. 3G, left). ET-1 aug-
mented the responses to the increase in temperature (2.5
± 0.6-fold, n = 10, for the first response after ET-1, Fig. 3I)
and, as illustrated for the experiment in Fig.3G, 3H,
shifted the threshold for TRPV1 activation to lower tem-
peratures (Fig. 3J).
HEK293 cells transfected with the same amounts of
TRPV1 and the ETBR showed a less prominent ET-1-
induced potentiation of capsaicin-stimulated TRPV1 cur-
rents when compared to that elicited by the ETAR (Fig. 4).
The first and second responses after ET-1 application were
2.9 ± 0.8-fold and 2.7 ± 0.5-fold (n = 5) that of the control,
respectively.
Role of protein kinases in the ETA receptor-mediated 
potentiation of TRPV1
Both ET receptor subtypes couple to G proteins from dif-
ferent families and each of the receptor types has its own
distinct profile of G proteins that it can activate. The ETAR
stimulates G proteins of the Gq, Gs and G12/13 families, the
ETBR activates G proteins of the Gqand Gi families e.g. [37-
40]. To investigate the signalling pathways activated and
possibly involved in the modulation of TRPV1 in HEK293
cells, we studied cAMP and inositol phosphate formation
in HEK cells stably expressing the ETAR or ETBR. ET-1
induced 22 ± 2.5- and 18 ± 2.0-fold increases in inositol
phosphate formation via ETARs and ETBRs, respectively
(Table 1). For HEK cells expressing the ETAR, a 34 ± 10.6-
fold increase in cAMP levels was noted. Cells expressing
the ETBR did not show any ET-1-induced increase in
cAMP.
From the data presented above, stimulation of the Gq-cou-
pled ETAR in HEK293 cells could potentiate TRPV1 by a
PLCβ-mediated breakdown of PIP2 or by the production
of DAG and activation of PKC. Alternatively, TRPV1
potentiation could be mediated by the activation of PKA.
We therefore studied the effects of PKC and adenylyl
cyclase (AC)/PKA activation on capsaicin-mediated
TRPV1 activation, and compared these with ET-1/ETAR-
mediated effects on TRPV1 activity. Application of the
phorbol ester, phorbol myristate acetate (1 µM), for 1
minute before the addition of capsaicin (10 nM) resulted
in a clear and strong potentiation of the capsaicin
responses that closely resembled the potentiation seen
with ET-1 (Fig. 5). In contrast to activation of PKC by
PMA, the activation of AC with forskolin (50 µM, Fig. 5)
or treatment with the membrane-permeable cAMP ana-
log, dibutyryl cAMP (dbcAMP; 5 mM), had comparatively
weak effects or no effect on TRPV1 currents, respectively.
After 1.5 minutes of treatment, forskolin increased cur-
rents 1.5 ± 0.1-fold (n = 4), but the effect after 4 minutes
of forskolin treatment was not significant. Similarily,
dbcAMP had no significant effect on current responses to
capsaicin; they were 0.97 ± 0.11-fold (n = 4, p = 0.802)
and 1.5 ± 0.5-fold (n = 4, p = 0.357) of the control, after
1.5 and 4 minutes of dbcAMP application, respectively.
To analyse the role of PKC activation in ET-1-mediated
potentiation of TRPV1, we tested the effect of the PKC
inhibitor BIM X on the potentiation of capsaicin-induced
TRPV1 currents in response to ET-1. Potentiation was
completely prevented by a 2 minute incubation with BIM
X (500 nM) prior to the ET-1 application (Fig. 6A). Con-
trol experiments performed in parallel on the same days
with cells transfected at the same time showed strong
Potentiation of capsaicin-activated currents in dorsal root  ganglion neurons by ET-1 Figure 2
Potentiation of capsaicin-activated currents in dorsal 
root ganglion neurons by ET-1. A, Recording of current 
at -60 mV showing responses to repetitive applications of 
capsaicin (10 nM) in a Ca2+-free extracellular solution. Appli-
cation of ET-1 (100 nM) at the time indicated by the bar 
resulted in a small increase in current during the ET-1 appli-
cation and a large potentiation of the capsaicin-activated cur-
rents. B, Results of a similar experiment to that in A which 
shows a larger current response to ET-1 application. C, Bar 
graph summarising the potentiation of capsaicin responses by 
ET-1 (100 nM) in ET-1-responsive rat DRG neurons. Control 
is the normalized capsaicin response before ET-1 application, 
after ET-1 the first (n = 9, p = 0.0066) and second (n = 8, p = 
0.017) normalized responses after ET-1 application.
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Potentiation of TRPV1 currents by ET-1 in HEK293 cells cotransfected with TRPV1 and the ETAR Figure 3
Potentiation of TRPV1 currents by ET-1 in HEK293 cells cotransfected with TRPV1 and the ETAR. A – C, Poten-
tiation of capsaicin-activated currents by ET-1. A, Recording of current at -60 mV showing the potentiation of responses to 
capsaicin (10 nM) by the application of ET-1 (100 nM). B, IV-relationships recorded at the times indicated by the numbers 1 – 4 
in A. C, Bar graph summarizing the potentiation of TRPV1 responses to capsaicin by ETAR activation in HEK293 cells. The bars 
show the normalized control response prior to ET-1 application and the normalized first (n = 10, p = 0.0009) and second (n = 
9, p = 0.0012) responses after ET-1 application. D – F, Potentiation of H+-activated currents by ET-1. D, ET-1 increased the 
amplitude of TRPV1 responses to pH 5.1. Currents were recorded at -60 mV and applications of pH 5.1 preceded by a solu-
tion of pH 6.8 to prevent the activation of endogenous ASICs. E, IV-relationships recorded at the times indicated by numbers 
in D. F, Bar graph summarizing the potentiation of the TRPV1 response to pH 5.1 by ET-1, and showing the normalized 
response before ET-1, and the first (n = 12, p < 0.0001) and second (n = 9, p = 0.0069) responses after ET-1. G – J, Potentia-
tion of heat-activated currents through TRPV1 by ET-1. G, Current recordings at -60 mV (upper traces) showing consecutive 
responses of a control cell to heating to 44°C (left), and responses from a cell treated with ET-1 after the first response to heat 
(right). The lower traces show the temperature recorded in the chamber close to the cell. H, I-V relationships recorded at the 
times indicated by the numbers in G. I, Bar graph summarizing the potentiation of the normalized first (n = 10, p = 0.0252) and 
second (n = 7, p = 0.0233) responses to heat after ET-1. J, Plot of the current-temperature relationships for the control 
response (filled squares) and the second response after ET-1 (open squares) from the experiment in G.
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potentiation (Fig. 6B). In contrast to the results after PKC
inhibition, potentiation still occurred after treatment with
the protein kinase inhibitor H89 (5 µM, n = 4), which at
this concentration most strongly inhibits PKA, and was
not significantly different from that without H89 (Fig. 6).
To confirm the pivotal role of PKC-mediated phosphor-
ylation in the modulation of TRPV1 by ET-1 using an
independent approach, we employed a mutant of TRPV1
which does not show PKC-mediated potentiation. The
PKC phosphorylation sites involved in PKC-mediated
enhancement of capsaicin-activated currents through
TRPV1 have been localized to S502 and S800 [41,42].
Mutation of either site to alanine leads to a very strong
reduction in sensitization of currents by PMA [41,42] and
by mediators like ATP that act via  the Gq/11-coupled
metabotropic P2Y1 receptor leading to an activation of
PKC [41]. We therefore tested the effects of ETAR activa-
tion on the TRPV1 mutant TRPV1-S800A. The ETAR was
coexpressed with YFP-tagged TRPV1-S800A in HEK293
cells. The mutant TRPV1-S800A differed from wild type
TRPV1 in that currents tended to increase with consecu-
tive responses, rather than decrease (compare the first and
second response to capsaicin in Fig. 7A). In contrast to
wild type TRPV1, no significant potentiation of capsaicin-
activated currents was observed on application of ET-1
(Fig. 7). It is unclear whether the slight increase after ET-1
in Fig. 7A results from run-up of channel currents or from
a very small potentiation that persisted in the mutant. The
inability to observe an effect does not result from the
briefer capsaicin application than that for the wild type
because the application was continued until the current
response was close to a plateau (Fig. 7A, lower trace). It is
clear, however, that the strong stimulatory effect of ETAR
activation is lost following mutation of the PKC phospho-
rylation site, consistent with sensitization resulting from
PKC-mediated phosphorylation.
Discussion
We show here that DRG neurons mainly express ETARs
and that their expression partially overlaps with the
expression of TRPV1. We also show that ET-1 potently
modulates the functional activity of TRPV1 in a subpopu-
ET-1 also potentiates capsaicin-activated currents in HEK293  cells cotransfected with TRPV1 and the ETBR Figure 4
ET-1 also potentiates capsaicin-activated currents in 
HEK293 cells cotransfected with TRPV1 and the 
ETBR. A, Current responses to capsaicin (10 nM) application 
were potentiated by the application of ET-1 (100 nM). B, Bar 
graph summarizing the effects of ET-1 on normalized capsai-
cin responses in cells cotransfected with TRPV1-YFP and the 
ETBR. Shown are the first (n = 7, p = 0.0102) and second (n = 
6, p = 0.0163) capsaicin response after ET-1 normalized to 
the capsaicin response before ET-1 application.
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Table 1: Synopsis of ET-1-mediated cAMP and inositol phosphate formation via ETA and ETB receptors
HEK ETAR HEK ETBR
-fold of control EC50 [nM] -fold of control EC50 [nM]
formation of inositol phosphates 22.3 ± 2.5 4.5 ± 1.2 18 ± 2.0 7.3 ± 1.7
formation of cAMP 34 ± 10.6 13.3 ± 3.2 n. i. n.a.
HEK293 cells stably expressing the ETAR or the ETBR were stimulated with increasing concentrations of ET-1 (up to 100 nM) in the presence of 10 
mM LiCl (inositol phosphate assays) for 60 min or 1 mM IBMX (cAMP assays) for 30 min. The amount of formed inositol phosphates was 
determined by anion exchange chromatography and cAMP was determined by cAMP RIA as described in Materials and Methods. Values are means ± 
SD of at least three independent experiments performed in duplicate. Duplicates differed by less than 10 %. n.i.: no increase, n.a.: not applicableMolecular Pain 2007, 3:35 http://www.molecularpain.com/content/3/1/35
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lation of sensory neurons and in HEK293 cells co-express-
ing the ETAR and TRPV1. A significant modulation of
TRPV1 activity was also found for HEK293 cells co-
expressing TRPV1 and ETBRs.
Even though the ETAR can stimulate pathways leading to
both PKA and PKC activation, receptor-mediated potenti-
ation of TRPV1 in HEK293 cells was predominantly medi-
ated by PKC. Evidence for this is that ET-1 effects were
completely inhibited by the PKC inhibitor BIM X, and
prevented in the PKC phosphorylation site mutant
TRPV1-S800A. There is also a strong similarity between
the extent of potentiation by ET-1 and that elicited by the
PKC-activating phorbol ester PMA. In contrast to the
effects of PKC activation and inhibition, the effects of PKA
activation by forskolin were comparatively weak, and
dbcAMP had no significant effect. Potentiation by ET-1
also persisted in the presence of H-89, an inhibitor of
PKA. In addition, some potentiation was observed with
the ETBR which did not increase cAMP. These results indi-
cate that, under the conditions used, i.e. in the absence of
extracellular Ca2+, ET-1-mediated potentiation is unlikely
to occur via Gs and AC, nor to a great extent via PKC-medi-
ated activation of AC. Because the cAMP/PKA pathway
acts, at least partly, by decreasing Ca2+-dependent desen-
sitization [32,43], we cannot rule out that this pathway
provides an additional component of potentiation of
TRPV1 by ET-1 at physiological Ca2+ concentrations. Our
work lends support to a recent study showing that PKC-ε
is involved in the ET-1-mediated enhancement of capsai-
cin-induced Ca2+ increases in sensory neurons, but which
did not show that TRPV1 is the target for PKC-ε-mediated
phosphorylation [19]. Our observation is also in line with
the finding that S800 is crucially involved in PMA-medi-
ated sensitization of TRPV1 via PKC-ε [44]. From our data,
we cannot rule out that different pathways may be
involved in the responses to ET-1 in sensory neurons, but
there is a striking similarity between the effects in DRGs
and in HEK293 cells. The evidence for an involvement of
PKC in potentiation by ET-1 supports studies showing an
involvement of PKC in potentiation of TRPV1 by bradyki-
nin via B2 receptors [26,27,31], ATP via Gq-coupled P2Y1
receptors [41,45], the chemokine CCL3 via CCR1 [46], 5-
HT via 5-HT2 receptors [47], and in some of the effects of
prostaglandins via EP1 or IP receptors [48], but contrasts
with that showing that the effects of bradykinin and NGF
result from PLC-mediated release of TRPV1 from inhibi-
tion by PIP2 [28,49]. The increase of TRPV1 currents in
response to PKC activation in sensory neurons most likely
results from a phosphorylation-induced increase in the
activity of channels at a given agonist concentration [50],
but has also been attributed to an increased recruitment of
intracellularly-stored vesicles carrying TRPV1 to the
plasma membrane [51].
In DRG neurons, we observed two effects of ET-1; poten-
tiation of responses to capsaicin and, in a smaller popula-
tion of neurons, the activation of an inward current. These
effects are very similar to those of bradykinin, which also
activates an inward current, most likely a cation current, in
some sensory neurons [26,52,53], and potentiates cur-
rents through TRPV1 [26,27,31]. It remains unclear
whether the channel activated by bradykinin is TRPV1
because not all heat-sensitive neurons with temperature
thresholds of 42°C, characteristic for TRPV1, show a cur-
rent response to bradykinin [26]. On the other hand, high
concentrations of bradykinin can shift the temperature
threshold of TRPV1 sufficiently to produce a current at
room temperature [27]. The inward current activated by
ET-1 was not characterized directly, but it differed from
TRPV1 currents in the absence of current noise for currents
of comparable amplitudes, and there was no link between
the amplitude of the ET-1-activated and capsaicin-acti-
vated currents. Other possible candidates for the ET-1-
activated channel include other cation channels, like e.g.
TRPA1, which has been shown to be activated by bradyki-
nin [54]. It is also notable that in HEK293 cells co-trans-
fected with TRPV1 and ETARs or ETBRs, ET-1 did not
induce a rapidly activating and inactivating inward cur-
rent like that in DRG neurons, but did result in a small
Potentiatory effects of forskolin and PMA onTRPV1 Figure 5
Potentiatory effects of forskolin and PMA onTRPV1. 
A, Adenylyl cyclase activation with forskolin (50 µM) resulted 
in a small increase in current responses to capsaicin (caps, 10 
nM) whereas application of the PKC activator PMA (1 µM) 
resulted in a large potentiation of responses to capsaicin. B, 
Bar graph showing the control and the first two normalized 
responses to capsaicin after forskolin (forskolin 1: n = 5, p = 
0.0271; forskolin 2: n = 4, p = 0.067) and PMA (PMA 1: n = 4, 
p = 0.0922; PMA 2: n = 4, p = 0.0088) application.
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slow increase in an outwardly-rectifying current that
resembled TRPV1. Thus, the molecular basis and nature of
the fast inward current seen in DRG neurons in response
to ET-1 remains to be clarified.
Our data at the cellular level support a role of potentiation
of currents through TRPV1 in ET-1-induced excitation of
nociceptors by increasing their sensitivity to algogenic
stimuli. Furthermore, ET-1 could produce an initial tran-
sient excitation of some neurons by the activation of an
inward current. Previous studies have postulated that part
of the effects of ET-1 on nociception occur via modulation
of TTX-resistant Na+ channels [20] shifting their potential
dependence of activation to more negative membrane
potentials leading to enhanced excitability of the sensory
neurons. Effects on Na+ channels have been observed with
the hyperalgesic modulators PGE2, 5-HT, epinephrine and
adenosine (for reviews see [55,56]), and may be mediated
by PKA or PKC activation [57]. Thus, the actions of ET-1
in sensory neurons involve contributions of Na+ channels
and TRPV1, and may be mediated by both PKA and PKC.
By its concerted actions on TRPV1 and Na+ channels, ET-1
Protein kinase C inhibitors, but not protein kinase A inhibitors prevent the potentiation of TRPV1 by ET-1 Figure 6
Protein kinase C inhibitors, but not protein kinase A inhibitors prevent the potentiation of TRPV1 by ET-1. A, 
Current trace from an experiment in which the PKC inhibitor BIM X (500 nM) was applied immediately prior to stimulation 
with ET-1 (100 nM) illustrating that BIM X treatment prevented potentiation by ET-1. B, Bar graph summarizing the effects of 
ET-1 on the first response to capsaicin after ET-1 in the absence (n = 6, p = 0.0156) and presence of BIM X (n = 7, p = 0.8964). 
C, Trace showing ET-1 potentiation of capsaicin-activated currents in the presence of the PKA inhibitor H-89. D, Bar graph 
summarizing the effects of ET-1 on the first (n = 4, p = 0.0953) and second (n = 4, p = 0.0275) capsaicin responses after treat-
ment with H-89. Cells were cotransfected with TRPV1-YFP and the ETAR.
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could increase the depolarization of sensory endings in
response to noxious stimuli and concomitantly reduce the
threshold for activation of a population of Na+ channels.
The effects of ET-1 on nociception are complex. Different
experimental models have been used to study the role of
ET-1 in nociception, and receptor subtype-specific ago-
nists and antagonists to identify the ET receptor subtype
mediating the effects. The pronociceptive actions of ET-1
have been reported to involve either ETARs [9,10,58-62]
or ETBRs [63,64], or both ETARs and ETBRs [12,65,66].
Our results indicate that the ETAR is expressed in sensory
neurons and could contribute to the algogenic effects of
ET-1 by sensitizing TRPV1. This suggestion is supported
by a recent study on mouse DRGs which showed that the
Ca2+ release in response to ET-1, and the potentiatory
effect of ET-1 on capsaicin-induced Ca2+ responses are
mediated exclusively by ETARs [19]. Even though the ETBR
is able to potentiate TRPV1 in HEK293 cells, the low level
of ETBR expression in DRG neurons indicates that the
algogenic effects of ETBR agonists [12,64] and the analge-
sic effects of ETBR antagonists [63-66] are more likely to
result from indirect effects on the ETBR in Schwann and
other glial cells where receptor expression is high [17]. It
is difficult to extrapolate from data obtained on single iso-
lated neurons to the situation in vivo, but our results could
explain the excitatory effects of ET-1 injection on nocicep-
tors and some of the amplification of responses to ther-
mal and mechanical stimuli. The rapid inward current, if
occurring in the periphery, could rapidly excite some ET
receptor-expressing nociceptive neurons. Thereafter, the
potentiation of TRPV1 could be responsible for the excita-
tion, and for the hyperalgesia and allodynia seen after ET-
1 application. Potentiation of TRPV1 with high ET-1 con-
centrations occurs rapidly and, although it decreases with
time, by extrapolating our data (e.g. those in Fig. 2A) can
probably persist for several tens of minutes. It is more dif-
ficult to explain the TRPV1-mediated prolongation of tac-
tile allodynia in response to low ET-1 concentrations
where a role of TRPV1 is only significant at times longer
than 30 minutes after ET-1 application [67]. While the
role of the ETAR in the action of ET-1 on nociception is rel-
atively clear, the role of the ETBR is less well understood.
The ETBR in glial cells and possibly in neurons is likely to
have pronociceptive effects, whereas the ETBR in keratino-
cytes has been reported to mediate the analgesic effects of
ET-1 and ETB agonists by inducing the release of β-endor-
phin [68].
Conclusion
Our results show that ET-1 potentiates TRPV1 via a PKC-
mediated effect and we suggest that this could be respon-
sible for a major part of the pain-producing and hyperal-
gesic effects of ET-1 observed in previous studies.
Methods
Isolation and culture of DRG neurons
Dorsal root ganglia (DRG) were isolated as described
recently [69]. In brief, DRG from lumbar segments L4 – L5
of male Wistar rats were isolated and placed in Minimal
Essential Medium (MEM, Biochrom AG, Berlin, Ger-
many) at 4°C. Thereafter, they were sequentially digested
with collagenase (type II; 3 mg/ml) for 50 min at 37°C,
and trypsin (type I; 0.25 mg/ml) for 10 min at 37°C. After
careful mechanical dissociation, cells were washed twice
and resuspended in fresh medium supplemented with
10% horse serum, 50 ng/ml NGF, 50 U/ml penicillin and
50 µg/ml streptomycin. Neurons were seeded on poly-l-
lysine-coated glass coverslips in 6-well culture plates 4 –
36 h before the experiments. Neurons were kept at 37°C
in an atmosphere of 5% CO2.
ET-1 does not potentiate capsaicin responses from the PKC  phosphorylation site mutant TRPV1-S800A Figure 7
ET-1 does not potentiate capsaicin responses from 
the PKC phosphorylation site mutant TRPV1-S800A. 
A, top, Current trace showing responses to capsaicin (10 
nM) before and after ET-1 (100 nM) application to a HEK293 
cell cotransfected with TRPV1-S800A and the ETAR. Bottom, 
Current response to capsaicin after ET-1 in top trace on an 
expanded time scale. B, Bar graph summarizing the effects of 
ET-1 on the first (n = 4, p = 0.0735) and second (n = 4, p = 
0.0921) capsaicin responses after ET-1 application recorded 
from TRPV1-S800A.
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Generation of plasmids encoding mutant TRPV1
To investigate the role of PKC-mediated phosphorylation
of TRPV1, a plasmid was generated, which encodes a
mutant TRPV1 in which serine 800 is replaced by alanine
(TRPV1-S800A). Site-directed mutagenesis was performed
with the QuickChange mutagenesis kit (Stratagene, La
Jolla, CA), using a plasmid encoding a rat TRPV1-YFP
fusion protein [70] and appropriate sense and antisense
oligonucleotides spanning the mutated triplet and 15
flanking nucleotides. The construct was verified by DNA
sequencing.
HEK culture
HEK293 cells were cultured in MEM-Earle medium (Bio-
chrom), supplemented with 10% (v/v) fetal calf serum
(Gibco/Invitrogen, Karlsruhe, Germany) and 100 U/ml
penicillin and 100 µg/ml streptomycin. Cells were plated
onto glass cover slips 24 – 48 h prior to transfection. The
cells were transiently transfected with 1 µg of the plasmid
pTRPV1-YFP [70] and 2 µg of the plasmid pETA-myc DNA
[71] or the plasmid containing the FLAG-tagged ETB DNA
[71] using 6 µl of FuGENE 6 Transfection Reagent (Roche
Diagnostics, Mannheim, Germany) in 94 µl of OptiMEM
medium (Gibco/Invitrogen) per 85 mm dish. In some
experiments, cells were transfected 1 – 2 days after plating
into 35 mm dishes using 9 µl TransIT (Mirus, Madison,
WI) in serum-free MEM-Earle medium, subsequently
trypsinized and plated onto glass coverslips 2 days after
transfection. No differences were observed between
results obtained with the two methods. Electrophysiolog-
ical experiments were performed 24 – 72 h after transfec-
tion.
Immunofluorescence analysis
Immunofluorescence analysis was performed as described
recently [69]. Freshly isolated DRG were embedded in Tis-
sue-Tek compound (OCT, Miles Inc., Elkhart, USA) and
frozen. Consecutive sections (9 µm) were prepared with a
cryostat and mounted onto gelatin-coated slides. To pre-
vent non-specific binding, the sections were incubated for
60 min in PBS containing 0.3% Triton X-100, 1% BSA, 4%
goat serum, and 4% horse serum (block solution). The
sections were then incubated overnight at 4°C with a
guinea pig polyclonal antibody against TRPV1 (1:1,000;
Chemicon, CA, USA) or S100 Antigen (1:200; Abcam,
Cambridge, UK) in combination with a peptide-derived
rabbit polyclonal antibody directed against the C termi-
nus of the ETAR (1:100) (Plant et al., 2006) or against the
N terminus of the ETBR (1:100) [71]. The tissue sections
were washed with PBS and then incubated with Texas red-
conjugated goat anti-rabbit antibody and FITC-conju-
gated donkey anti-guinea pig antibody. Thereafter, sec-
tions were washed with PBS, mounted in vectashield
(Vector Laboratories, Burlingame, CA, USA) and viewed
with a Zeiss 510 laser scanning microscope (Zeiss,
Oberkochen, Germany).
cAMP and inositol phosphate measurements
Determination of inositol phosphates and of cAMP was
performed as described previously [72]. In brief, HEK293
cells stably expressing ETARs or ETBRs were seeded onto
24-well plates (100,000 cells/well). For inositol phos-
phate determination, cells were incubated the following
day with 74 kBq/ml myo- [2-3H]inositol (specific activity
370 – 740 GBq/mmol; Amersham Biosciences) for 20 h at
37°C. Cells were then washed with DMEM, 10 mM
HEPES, 0.5% BSA, 10 mM LiCl, and finally stimulated
with buffer or increasing concentrations of ET-1 (10 pM to
100 nM) for 60 min at 37°C. Cells were then lysed with
0.1 M NaOH, and inositol phosphates isolated from
cleared supernatants by anion exchange chromatography.
For the determination of cAMP, cells were washed with 1
ml of stimulation medium (DMEM without fetal calf
serum, supplemented with 10 mM HEPES, 0.5% BSA,
0.25 mM 3-isobutyl-1-methylxanthine) and incubated for
30 min at 37°C with buffer or increasing concentrations
of ET-1 (10 pM to 100 nM). Cells were extracted with 750
µl of 0.1% trifluoroacetic acid, 0.005% Triton X-100 for
30 min at 4°C. After acetylation of the samples, the cAMP
content was determined using 125I-cAMP-tyrosylmethyl-
ester (10,000 cpm, specific activity 81.4 TBq/mM,
Biotrend, FRG) and polyclonal rabbit anti-cAMP-anti-
body (final dilution 1:160,000). After an overnight incu-
bation at 4°C, the antibody-bound fraction was
precipitated, and the radioactivity of the precipitate was
determined in a β-counter.
125I-ET-1 binding analysis
Binding analysis was performed as described [73,74]. In
brief, membranes (5 µg) of DRGs were incubated in a
final volume of 200 µl Tris/BAME buffer with increasing
concentrations of 125I-ET-1 (18 to 1000 pM) in the
absence or presence of unlabelled ET-1 (1 µM) (to detect
ETARs and ETBRs) for 2 hours at 25°C. The ratio of ETA and
ETBR expression was determined by 125I-ET-1 saturation
binding analysis using ET-1 (1 µM, total binding),
IRL1620 (1 µM, ETBR-specific binding) or BQ123 (10 µM,
ETAR-specific binding) as competing ligands. The samples
were then transferred onto GF/C filters (Whatman Inter-
national Ltd., Maidstone, UK), and washed twice with PBS
using a Brandel cell harvester. Radioactivity was deter-
mined in a γ-counter. Data were analyzed with RadLig
Software 4.0 (Cambridge, UK).
Patch clamp recordings
Recordings of whole cell currents from single cells were
made with an EPC-7 or EPC-10 amplifier using Pulse soft-
ware (HEKA, Lambrecht, Germany) as described previ-Molecular Pain 2007, 3:35 http://www.molecularpain.com/content/3/1/35
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ously [75]. Experiments were performed using the
standard whole cell mode of the patch clamp technique.
Cells were held at a potential of -60 mV and the current
recorded using XChart (HEKA). In HEK293 cells, ramps
from -100 to +100 mV with a duration of 400 ms were
applied at a frequency of 0.2 Hz. Ramp data were acquired
at a frequency of 4 kHz after filtering at 1 kHz.
The standard pipette solution contained 100 mM
CH3O3SCs (cesium methane sulfonate), 25 mM CsCl, 3
mM MgCl2, 2 mM Na2ATP, 3.62 mM CaCl2, 10 mM
EGTA, 30 mM HEPES (pH 7.2 with CsOH). Pipette tips
were filled with the same solution without ATP to avoid
the activation of purinergic receptors prior to seal forma-
tion. The standard extracellular solution contained: 140
mM NaCl, 5 mM CsCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM
glucose, 10 mM HEPES (pH 7.4 with NaOH). For Ca2+-
free solutions, Ca2+ was omitted and 0.5 mM EGTA added.
Experiments were performed at room temperature 20 –
25°C. Solutions were applied by bath perfusion. In most
cases, with the exception of Fig. 2B, which was not used
for quantification of the response, capsaicin was applied
until currents approached a steady state value. In experi-
ments on the effects of heat, bath temperature was meas-
ured using a thermistor placed close to the cell studied
and recorded using XChart. The test solution was pre-
heated to appropriate temperatures using a water jacket
connected to a water bath.
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